Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: dr.praveen who wrote (21361)	9/19/2006 8:06:32 PM
From: Biomaven	Respond to of 52153

Readers of this thread actually got my opinion that aspirin and ibuprofen don't mix well nearly two years ago, just after the time the Vioxx news broke. (This was in response to a question about whether anyone had studied combinations of aspirin and various NSAIDS and whether the absence of aspirin might have accounted for the apparent bad cardiac effects of other NSAIDS). One thing that does emerge is that specifically ibuprofen plus aspirin is NOT a good idea, for reasons that are unclear. Message 20890747 Peter

To: dr.praveen who wrote (21361)	9/20/2006 10:00:48 AM
From: Biomaven	Read Replies (2) \| Respond to of 52153

Speaking of POZN, this PR was released today: Press Release Source: POZEN; GlaxoSmithKline New Analysis Shows Patients Who Treat Their Migraine Pain Early With Trexima(TM) (Sumatriptan Succinate/Naproxen Sodium) Have Higher Sustained Pain-Free Rates Than Those Who Treat Late Wednesday September 20, 9:22 am ET Patients Who Treated Early Were More Likely to be Pain-free from 2 Through 24 Hours LONDON, Sept. 20 /PRNewswire-FirstCall/ -- (NYSE: GSK - News; Nasdaq: POZN - News) -- Migraine sufferers frequently cite lack of recurrence of migraine symptoms as one of the most desired attributes of an acute migraine treatment. Now, a new analysis of four studies showed that patients who treated their migraines with Trexima while pain was mild and within one hour of the start of pain were nearly twice as likely to be pain free at 2 hours, and remain pain free through 24 hours, than those who waited until the pain was more severe. These findings were presented today at the 16th Migraine Trust International Symposium in London. ADVERTISEMENT "Patients are often hesitant to treat their migraine early as they are concerned that the medicine will wear off and their symptoms will return. These results are exciting because they may help dispel this myth." said Jan Lewis Brandes, MD, director of the Nashville Neurosciences Institute and lead study investigator. "These findings show that by treating a migraine early with a product like Trexima patients are more likely to still be pain free 24-hours later than if they wait to treat in the later stages of a migraine." Trexima, the proposed brand name for a single tablet containing sumatriptan 85 mg as the succinate salt, formulated with RT Technology(TM), and naproxen sodium 500mg, is currently under review by the United States Food and Drug Administration (FDA) for the acute treatment of migraines in adults. Migraine pain is believed to be induced not only by the widening of blood vessels, or vasodilation, but also by inflammation, leading to increased nociception (perception of pain) and sensitization of nerves. This complex sequence of events occurs long before patients feel pain and take their medication. About the Studies Data were derived from identical, randomized, multi-center, double-blind, placebo controlled studies. This analysis evaluated sustained pain-free responses, defined as pain free at 2 hours and maintained through 24 hours, in these studies. Two studies evaluated the clinical benefits of treating migraine early (while pain was mild and within one hour of the start of pain) with sumatriptan/naproxen sodium or placebo. These findings showed: -- Significantly more patients who treated with sumatriptan/naproxen sodium achieved a sustained pain-free response (45 percent and 40 percent) compared to patients who received placebo (12 percent and 14 percent). Two studies evaluated the benefits of treating migraine late (when pain is moderate to severe) with sumatriptan/naproxen sodium; 85 mg of sumatriptan, formulated with RT Technology; 500 mg of naproxen sodium; or placebo. -- Significantly more patients who treated with sumatriptan/naproxen sodium achieved a sustained pain-free response (23 percent and 25 percent) compared to patients who treated with sumatriptan alone (14 percent and 16 percent), naproxen sodium alone (10 percent and 10 percent), or placebo (7 percent and 8 percent).1 Sumatriptan/naproxen sodium was well-tolerated in all four studies. The most common adverse events were dizziness, somnolence, nausea, tingling, dry mouth, dyspepsia, and chest discomfort. Of course patients would likely do even better if they could manage the hard task of taking two Alleve tabs (which is nearly 500mg of Naproxen) and one of the second-generation triptans... Peter